GET DAILY SIGNALSAprea Therapeutics (APRE): Analyst Targets Suggest +700% Upside from Current Levels
Key Takeaways
- The central target of $3.85 is the arithmetic mean of five verified analyst price targets, rounded, not any single analyst's view or a published consensus.
- The latest verified close is about $0.48, meaning the target implies a gain of roughly 700% — a very large move for a clinical-stage micro-cap.
- Individual targets range widely, from $1.20 (H.C. Wainwright) to $6.00 (Wedbush), reflecting a binary, data-driven biotech story.
- Supporting factors include early Phase 1 activity for lead asset APR-1051, a cash runway into early 2028, and a fresh $30 million financing.
- Key risks include no approved products or meaningful revenue, ongoing net losses, thin trading liquidity, and dependence on near-term clinical data.
- You can track the latest developments on additional pages, including Major News, Today's Price Move, the Forecast, and Earnings.
- For automated, AI-driven stock and ETF signals, explore Trending AI Robots.
Analyst Price Targets for APRE
Aprea Therapeutics, Inc. (APRE) is a clinical-stage precision oncology company headquartered in Doylestown, Pennsylvania. It is a stock, not an exchange-traded fund, and it has meaningful — though divergent — analyst coverage. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
A review of five current, individually attributable price targets produced a range of $1.20 to $6.00 and an arithmetic mean of roughly $3.84, rounded to a central target of $3.85. The targets reviewed were: H.C. Wainwright (Joseph Pantginis) at $1.20 (Aug. 13, 2026); Ladenburg Thalmann (Kevin DeGeeter) at $2.00, an initiation (Oct. 14, 2026); Oppenheimer (Jay Olson) at $5.00 (Aug. 13, 2026); Maxim Group (Jason McCarthy) at $5.00 (Aug. 14, 2026); and Wedbush (Robert Driscoll) at $6.00 (May 14, 2026).
Every one of these firms rates APRE a Buy or Outperform, so the disagreement is not about direction but magnitude. The cautious end of the range ($1.20) reflects H.C. Wainwright's sharp cut from $4.00 earlier in 2026, while Wedbush has trimmed its target gradually from $11.00 down to $6.00. This widening spread is typical of pre-revenue biotechs whose value hinges on trial readouts rather than earnings.
Current Market Position and Path Toward the Target
With shares trading near $0.48 and a 52-week range of roughly $0.41 to $1.49, reaching $3.85 would require an advance of approximately 700%. By any measure, that is a very large move, and it would imply a full re-rating of a company with a market capitalization of only about $6 million.
The plausible path runs through clinical, not financial, milestones. Aprea's lead program, APR-1051, is an oral WEE1 kinase inhibitor in the Phase 1 ACESOT-1051 dose-escalation study. Early data have shown partial responses and stable disease across multiple tumor types with manageable tolerability, and the company is expanding into uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer. Each favorable readout has the potential to compress the discount at which the stock trades relative to the analyst range.
Factors That Could Support a Move Toward the Target
- Clinical momentum: Early anti-tumor activity for APR-1051, presented at ASCO 2026 and slated for further updates in Q4 2026, is the central value driver.
- Balance-sheet durability: Cash of about $46.5 million as of March 31, 2026, is expected to fund operations into the first quarter of 2028, reducing near-term dilution risk.
- Fresh capital: A $30 million oversubscribed private placement led by Soleus Capital closed in March 2026, signaling institutional support.
- Intellectual property: A strengthened DDR (DNA damage response) patent portfolio extends potential exclusivity well into the future.
Factors That Could Prevent the Target From Being Reached
- No approved products: Aprea generates negligible revenue and remains loss-making, so the equity value rests almost entirely on clinical outcomes.
- Binary trial risk: Dose-escalation results for WEE1 inhibitors can fail to translate into durable efficacy at later stages.
- Micro-cap dynamics: With a roughly $6 million market cap and low float, the stock is vulnerable to wide price swings and limited institutional liquidity.
- Pipeline consolidation: The ATR inhibitor ATRN-119 was strategically paused in 2025, narrowing the near-term story to APR-1051.
Technical Levels and Market Structure
APRE has been in a prolonged downtrend, touching an all-time low near $0.41 in late October 2026 and trading far below its 52-week high of $1.49. That $0.41 area now functions as the key support level to defend, while $1.49 represents a distant but significant resistance level. Reaching $3.85 would require not only breaking above $1.49 but sustaining a re-rating well beyond any level seen in the trailing year.
Time Horizon and What Investors Should Monitor
Analyst price targets for biotech names generally reflect a roughly 12-month research horizon, though firms do not always state this explicitly and individual assumptions differ. The most important upcoming items are the next quarterly results (around mid-November 2026), the Q4 2026 update from the ACESOT-1051 Phase 1 trial, and any analyst target revisions that follow. Investors should also watch enrollment progress in the ovarian and uterine cancer expansion cohorts and any further financing announcements.
Final Assessment
Can APRE reach $3.85? The question frames a very large gap: shares near $0.48 would need to appreciate roughly 700% to reach the average of the five analyst targets reviewed. That mean conceals extraordinary disagreement — from $1.20 at the low end to $6.00 at the high end — because Aprea's value hinges on clinical data for APR-1051 rather than established revenue. Supportive factors include early signs of anti-tumor activity, a funded runway into 2028, and fresh institutional capital, while the principal obstacles are the absence of an approved product, persistent losses, and the inherent binary risk of early-stage oncology trials. The central target should be read as a directional expression of analyst optimism, not a forecast. What matters next is whether the Q4 2026 clinical update substantiates the early activity, and whether the financing remains sufficient to reach meaningful data milestones.
Using AI Tools to Complement Research
In my own analysis, I find Tickeron's AI Daily Buy/Sell Signals helpful for layering data-driven insights on top of fundamental work. The tool monitors thousands of stocks and ETFs in real time, generating Buy, Sell, or Hold signals based on technical behavior and market shifts. It offers a practical way to spot trends or confirm ideas without replacing manual review, and I have found it useful when evaluating names like APRE alongside clinical developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
APRE's RSI Oscillator climbs out of oversold territory
The RSI Indicator for APRE moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 53 similar instances when the indicator left oversold territory. In 44 of the 53 cases the stock moved higher. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 71 cases where APRE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +19.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where APRE advanced for three days, in 151 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
APRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on APRE as a result. In 85 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
APRE moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for APRE crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where APRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for APRE entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 18 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.159) is normal, around the industry mean (3.162). P/E Ratio (-0.516) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. APRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage biopharmaceutical company
Industry Biotechnology
Advertisement